Brief: Trevi Therapeutics - Data From Full Set Of Subjects In Completed Phase 2 Canal Trial In Chronic Cough In Ipf Expected In Q3 Of 2022
11/08/2022 22:11
Aug 11 (Reuters) - Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS - DATA FROM FULL SET OF SUBJECTS IN
COMPLETED
PHASE 2 CANAL TRIAL IN CHRONIC COUGH IN IPF EXPECTED IN Q3 OF
2022
* TREVI THERAPEUTICS INC QTRLY LOSS PER SHARE $0.14
Source text for Eikon: ID:nPn5XhrYKa
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million